Pimavanserin

Generic Name: Pimavanserin

Brand Names: Nuplazid

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₄FN_₃O_₂

CAS Number: 706779-91-1

Unique Ingredient Identifier: JZ963P0DIK

Background: Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT and HT receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pim...

Indication: 用于伴随帕金森氏病精神病幻觉和妄想的治疗。

Associated Conditions: Delusions, Hallucinations

Associated Therapies: -

Clinical Trials

Psilocybin Mechanism of Action (MOA)

Phase 2

Not yet recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: Psilocybin
Drug: Pimavanserin
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2024-10-26

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT06592833

Locations: 🇺🇸
Center for Psychedelic Therapy Research, New York, New York, United States

Pimavanserin for Sleep in Parkinson Disease

Early Phase 1

Withdrawn

Conditions: Parkinson Disease

Interventions: Drug: Pimavanserin

First Posted Date: 2023-04-03

Last Posted Date: 2024-12-20

Lead Sponsor: State University of New York - Downstate Medical Center

Target Recruit Count: 10

Registration Number: NCT05796167

Locations: 🇺🇸
SUNY Downstate Health Sciences University, Brooklyn, New York, United States

Comparing Antipsychotic Medications in LBD Over Time

Phase 4

Recruiting

Conditions: Dementia With Lewy Bodies
Parkinson's Disease Psychosis

Interventions: Drug: Quetiapine
Drug: Pimavanserin

First Posted Date: 2022-10-21

Last Posted Date: 2024-10-30

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 94

Registration Number: NCT05590637

Locations: 🇺🇸
University Health System, San Antonio, Texas, United States
🇺🇸
UT Health Science Center - San Antonio, San Antonio, Texas, United States

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Phase 2

Recruiting

Conditions: Irritability Associated With Autism Spectrum Disorder

Interventions: Drug: Pimavanserin

First Posted Date: 2022-09-27

Last Posted Date: 2024-12-06

Lead Sponsor: ACADIA Pharmaceuticals Inc.

Target Recruit Count: 228

Registration Number: NCT05555615

Locations: 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇵🇱
MedicMental Indywidualna Specjalistyczna Praktyka Lekarska Monika Szewczuk-Boguslawska, Wrocław, Poland
🇷🇸
Institute of Mental Health, Belgrade, Serbia

and more 41 locations

Pimavanserin for the Treatment of Irritability Associated with Autism Spectrum Disorder

Phase 2

Completed

Conditions: Irritability Associated with Autism Spectrum Disorder

Interventions: Drug: Placebo
Drug: Pimavanserin

First Posted Date: 2022-08-31

Last Posted Date: 2024-11-11

Lead Sponsor: ACADIA Pharmaceuticals Inc.

Target Recruit Count: 237

Registration Number: NCT05523895

Locations: 🇺🇸
Southwest Autism Research & Resource Center, Phoenix, Arizona, United States
🇺🇸
Cortica Inc. (Glendale), Glendale, California, United States
🇺🇸
Cortica Inc. (San Rafael), San Rafael, California, United States

and more 54 locations

Pimavanserin for Insomnia in Veterans With PTSD

Phase 2

Recruiting

Conditions: Post-traumatic Stress Disorder
Insomnia

Interventions: Drug: pimavanserin
Other: Placebo

First Posted Date: 2022-07-01

Last Posted Date: 2024-06-27

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 60

Registration Number: NCT05441280

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Phase 4

Recruiting

Conditions: Parkinson Disease
Neurodegenerative Diseases
Parkinson Disease Psychosis

Interventions: Drug: Pimavanserin

First Posted Date: 2022-05-03

Last Posted Date: 2024-02-28

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 75

Registration Number: NCT05357612

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Phase 4

Withdrawn

Conditions: Insomnia Chronic
Posttraumatic Stress Disorder

Interventions: Drug: Pimavanserin

First Posted Date: 2021-03-22

Last Posted Date: 2023-03-24

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT04809116

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States

Pimavanserin Treatment in TS

Early Phase 1

Completed

Conditions: Tourette Syndrome
Tardive Dyskinesia

Interventions: Drug: Pimavanserin

First Posted Date: 2021-03-12

Last Posted Date: 2021-03-12

Lead Sponsor: Joseph Jankovic

Target Recruit Count: 10

Registration Number: NCT04794413

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Phase 3

Active, not recruiting

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Pimavanserin

First Posted Date: 2020-08-31

Last Posted Date: 2023-08-16

Lead Sponsor: ACADIA Pharmaceuticals Inc.

Target Recruit Count: 454

Registration Number: NCT04531982

Locations: 🇦🇷
623-Clinica Privada de Salud Mental Santa Teresa de Avila, La Plata, Argentina
🇧🇬
586-Medical Center Mentalcare OOD, Plovdiv, Bulgaria
🇨🇿
583-Narodni ustav dusevniho zdravi, Klecany, Czechia

and more 99 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy